A cross-sectional study of 772 pediatric and adolescent patients with moderate-to-severe atopic dermatitis revealed distinct age-related differences in disease burden and treatment patterns.

A comprehensive meta-analysis of five phase III trials involving 2,855 patients demonstrates that perioperative immunotherapy combined with chemotherapy significantly improves overall survival, event-free survival, and pathological complete response rates compared to chemotherapy alone in resectable non-small cell lung cancer.

Diamyd Medical's DIAGNODE-3 trial, a Phase 3 study for Type 1 Diabetes, has recruited 180 patients, surpassing the target for its early readout planned in March 2026.

Oral decitabine and cedazuridine will be evaluated in the NIH's myeloMATCH program, targeting genetic mutations in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).

Researchers at WEHI have identified WEHI-3773, a small molecule that can selectively block cell death by targeting the BAX protein and preventing its recruitment to mitochondria.

A Phase II study in China reveals belumosudil yields a 73.3% overall response rate (ORR) in patients with chronic graft-versus-host disease (cGVHD).

Enveric Biosciences' lead neuroplastogen candidate EB-003 demonstrated statistically significant improvements in a preclinical mouse model of severe chronic depression, with effects comparable to the approved antidepressant imipramine.

Phase II trials suggest that androgen deprivation therapy (ADT) combined with second-generation agents shows promise, with favorable pathological complete response (pCR) and minimal residual disease (MRD) rates.

AskBio has announced the randomization of the first participants in its Phase II gene therapy trial targeting Parkinson’s disease, marking a significant step forward in the development of AAV gene therapy technology and therapeutics.

Neoadjuvant short-course radiation therapy (SCRT) with cadonilimab and chemotherapy demonstrated a 37% pathological complete response (pCR) rate in pMMR/MSS locally advanced rectal cancer.

Real-world data shows that LONSURF combined with bevacizumab significantly improves overall survival in patients with metastatic colorectal cancer (mCRC).

ALX Oncology's CD47-blocking therapy evorpacept demonstrated significant improvement in overall response rates and progression-free survival in HER2-positive gastric cancer patients. The drug nearly tripled the response rate compared to standard therapy, achieving 48.9% ORR versus 24.5% in the control group, while maintaining a favorable safety profile.

QX004N, a novel IL-23 inhibitor, achieved PASI 75 in 100% of patients across multiple dose groups at week 12 in a Phase 1b trial for moderate to severe plaque psoriasis.

The EMERALD-1 trial demonstrated that adding Imfinzi (durvalumab) and bevacizumab to TACE therapy significantly improved progression-free survival in unresectable hepatocellular carcinoma. However, Imfinzi alone with TACE failed to show significant benefit, raising questions about the individual contribution of the PD-L1 inhibitor to the treatment's success.

Phase 2 LEGEND trial demonstrates that Inventiva's lanifibranor, alone or combined with Jardiance, significantly improves liver health and metabolic parameters in patients with metabolic dysfunction-associated steatohepatitis (MASH) and type 2 diabetes. The positive results, presented at the SLD Summit 2025, show reduced blood sugar levels and improved liver health markers, supporting ongoing Phase 3 development.

MD Anderson researchers identified TTF-1 as a predictive biomarker for survival outcomes in advanced KRAS G12C-mutated non-small cell lung cancer patients treated with sotorasib.

The FDA has approved a new cardiovascular risk reduction indication for Eli Lilly's Trulicity (dulaglutide) in type 2 diabetes patients. This approval, based on the REWIND trial, makes Trulicity the first medication approved for both primary and secondary prevention of major adverse cardiovascular events (MACE) in type 2 diabetes patients.

Bristol-Myers Squibb's immunotherapy combination of Opdivo and Yervoy has demonstrated superior survival benefits in first-line hepatocellular carcinoma treatment, with FDA decision expected by April 2024. The therapy showed a 36% objective response rate compared to 13% for standard treatments, potentially offering a new option for patients with unresectable liver cancer.

The RAPID trial's 16-year follow-up data demonstrates that patients with early-stage classic Hodgkin lymphoma who achieve PET-negative status after three cycles of ABVD chemotherapy can safely avoid radiation therapy without compromising survival. This landmark finding, along with new data on bleomycin omission and novel combination therapies, represents a significant advancement in treatment de-escalation strategies.

Cartesian Therapeutics secured FDA agreement for Phase 3 trial of Descartes-08 in myasthenia gravis, potentially leading to BLA submission.